Genmab — Juni 2023
-
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023 https://ir.genmab.com/news-releases/news-release-details/genmab-showcases-data-comprehensive-epcoritamab-development
-
Both Talquetamab and Epcoritamab on the COMP agenda for next week under '4. Review of orphan designation for orphan medicinal products
at time of initial marketing authorisation' https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-13-15-june-2023_en.pdf -
results from 2 cohorts in EPCORE NH2 investigating epcoritamab+rituximab & lenalidomide in patients with R/R FL. This combination showed potent anti-tumor activity and a manageable safety profile in patients with high-risk disease #lymsm https://twitter.com/lymphomahub/status/1667162491560837120
-
@NBahlis
presents results of the TRIMM-2 trial (talquetamab + daratumumab), targeting GPRC5D & CD38, ORR of 84% w/ response rate within 1st round of therapy.
**Impressively, 78.6% pts were refractory & heavily pre-exposed to a CD38 https://twitter.com/MyelomaCanada/status/1667475172201201664 https://twitter.com/MM_Hub/status/1667475083022024707 -
Follicular #lymphoma (#FL) accounts for ~20% of all non-Hodgkin’s lymphoma (NHL) cases globally and is the most common subtype of indolent, or slow growing, NHL. https://twitter.com/Genmab/status/1667275399364001793
-
Carvykti: https://haematologisktidsskrift.dk/sygdomme/myeloma/1190-finale-cartitude-1-data-storste-pfs-gevinst-for-tungt-forbehandlede-rrmm-patienter-til-dato.html. https://haematologisktidsskrift.dk/sygdomme/myeloma/1194-forste-data-fra-cartitude-4-meget-flotte-responser-hos-lenalidomid-refraktaere-myelomatose-patienter.html
-
EPCORE FL-1 closes further enrollment to one of the groups ; i assume this means the correct dose is found and they no longer need to continue that cohort. Saves recruitement of 122 patients as Enrollment goes from 642 to 520 https://www.clinicaltrials.gov/ct2/history/NCT05409066?A=47&B=48&C=merged#StudyPageTop
-
New trial - Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial https://www.clinicaltrials.gov/ct2/show/NCT05898646
-
Godmorgen
-
Så er det vel i aften, der er Fireside hos GS https://event.webcasts.com/starthere.jsp?ei=1618997&tp_key=ab369db32b&tp_special=8
-
Opdaterede EPCORE NHL-2-data støtter op om epcoritamab + R-CHOP i 1L til højrisiko DLBCL https://haematologisktidsskrift.dk/sygdomme/lymfoma/1201-opdaterede-epcore-nhl-2-data-stotter-op-om-epcoritamab-r-chop-i-1l-til-hojrisiko-dlbcl.html
-
Genmab, l'autre success-story danoise de la santé https://www.zonebourse.com/cours/action/GENMAB-A-S-63733191/actualite/Genmab-l-autre-success-story-danoise-de-la-sante-44098213/?utm_medium=RSS&utm_source=googlenews&utm_content=20230613
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind